Shared on24 Jul 25Fair value Increased 6.13%
With Glenmark Pharmaceuticals' future P/E ratio edging up from 31.26x to 32.17x while net profit margin remains stable, the consensus analyst price target is unchanged at ₹2061. What's in the News Glenmark launched TEVIMBRA® (tislelizumab), an anti-PD-1 monoclonal antibody for NSCLC and ESCC, marking its entry into immune-oncology in India.
Shared on23 Apr 25Fair value Increased 0.30%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on17 Apr 25Fair value Decreased 0.091%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on09 Apr 25Fair value Decreased 0.75%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on02 Apr 25Fair value Decreased 6.13%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on26 Mar 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on19 Mar 25Fair value Decreased 0.98%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.